BioSpace News Archive

Drug Development

Positive Data Back Blueprint’s Bid for sNDA in Systemic Mastocytosis

Blueprint Medicines’ Ayvakit is headed to the FDA for a new indication after the drug hit the mark in Part 2 of the PIONEER trial for non-advanced systemic mastocytosis.

August 17, 2022
·
2 min read
·
Mark Terry
Policy

In Historic Ruling, FDA Allows Sale of Over-the-Counter Hearing Aids

The FDA expects to foster innovation and competition among manufacturers, which would lower the prices of hearing aids without compromising their quality.

August 17, 2022
·
2 min read
·
Tristan Manalac
Business

Ambrx Announces Abrupt Leadership Change as Longtime Executive Tian Replaced

Kate Hermans has taken over the reins of Ambrx as interim CEO following the abrupt departure of Feng Tian.

August 17, 2022
·
3 min read
·
Alex Keown
Sacroiliac Fusion Implants Market: Increase in the Number of Skilled Orthopedic Surgeons to Drive the Market

Wilmington, Delaware, United States, Transparency Market Research Inc. – Sacroiliac joints (SI) are joints between the sacrum and ilium bones of the pelvis.

August 17, 2022
·
6 min read
Anxiety Disorder and Depression Treatment Market Is Expected To Reach USD 19.53 Billion By 2028

The Global Anxiety Disorder and Depression Treatment Market size is forecast to reach USD 19.53 Billion by 2028, registering a CAGR of 2.4% over the forecast period, according to a new report by Reports and Data.

August 17, 2022
·
6 min read
Drug Development

Paxlovid Rebound: RWE Analysis and Alternative Therapies in Development

Researchers at Case Western University looked at the real-world experiences of 13,644 patients who were treated with Paxlovid or Lagevrio (molnupiravir) during the first half of 2022.

August 17, 2022
·
5 min read
·
Gail Dutton
Metastatic urothelial carcinoma Market Size Worth USD 2.71 Billion By 2027

According to the current analysis of Emergen Research, the Metastatic urothelial carcinoma market was valued at USD 725.9 million in 2019 and is expected to reach USD 2.71 billion by the year 2027, at a CAGR of 17.9%.

August 17, 2022
·
6 min read
bluebird bio Scores First U.S. Approval for Lentiviral Vector Gene Therapy

The approval, which was made under Priority Review, is a watershed moment in gene therapy as it marks the first FDA green light for a lentiviral vector.

August 17, 2022
·
4 min read
·
Alex Keown
Business

Sanofi, Atomwise Ink Potential $1B+ R&D Deal

Atomwise inked a strategic research-and-development deal with Sanofi to use the AtomNet platform to identify and research up to five drug targets.

August 17, 2022
·
3 min read
·
Mark Terry
Drug Development

Phase III Flop Ends Sanofi’s SERD Breast Cancer Candidate

All other ongoing and pending studies of Sanofi’s amcenestrant, including the early-stage breast cancer trial AMEERA-6, will also be discontinued.

August 17, 2022
·
3 min read
·
Tristan Manalac